2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)
Abstract: AimsTo compare the efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of glargine 100 U/ml (Gla-100) in insulin-naïve people with type 2 diabetes using oral glucose-lowering drugs.MethodsThe EDITION 3 study was a multicentre, open-label, parallel-group study. Participants were randomized to Gla-300 or Gla-100 once daily for 6 months, discontinuing sulphonylureas and glinides, with a dose titration aimed at achieving pre-breakfast plasma glucose concentrations of 4.4–5.6 mmol/l (80–100 mg/…
Search citation statements
Paper Sections
Select...
229
70
58
12
Citation Types
44
511
12
12
Year Published
1993
2026
Publication Types
Select...
292
7
2
1
Relationship
6
296
Authors
Journals
Cited by 298 publications
(579 citation statements)
References 26 publications
44
511
12
12
“…As expected, Gla-300 was associated with lower rates of hypoglycemia compared with NPH insulin. Our findings are consistent with previous results in the EDITION trials in T2D patients where Gla-300 consistently reduced nocturnal hypoglycemia compared with Gla-100 with no differences in HbA1c [ 2 , 3 ]. With comparable HbA1c and FPG achieved between treatment groups, there were notable differences in GV and TIR between the Gla-300 and NPH groups that varied by time of day.…”
Section: Discussionsupporting
confidence: 92%
“…As expected, Gla-300 was associated with lower rates of hypoglycemia compared with NPH insulin. Our findings are consistent with previous results in the EDITION trials in T2D patients where Gla-300 consistently reduced nocturnal hypoglycemia compared with Gla-100 with no differences in HbA1c [ 2 , 3 ]. With comparable HbA1c and FPG achieved between treatment groups, there were notable differences in GV and TIR between the Gla-300 and NPH groups that varied by time of day.…”
Section: Discussionsupporting
confidence: 92%
“…FPG reductions observed at month 6 in the LATAM participants (LS mean change À50.58 mg/dl) were lower than those in the global ATOS 23 Overall, the incidence rates of documented symptomatic and severe hypoglycaemia (at night and at any time of the day) were low in ATOS LATAM. This finding is consistent with the aforementioned real-world studies, 20,23,26 RCTs 15,19 and the CONCLUDE trial. 31 It is important to note that none of the participants showed clinically relevant documented hypoglycaemia (blood glucose < 54 mg/dl [<3.0 mmol/L]), despite moderate reductions in HbA1c, FPG and fasting SMBG.…”
Section: Discussionsupporting
confidence: 92%
“…Studies in several Western populations with type 2 diabetes in the EDITION programme (EDITION 1, 2 and 3) have shown no difference in glycaemic control but less hypoglycaemia with Gla-300 than Gla-100 [10][11][12]. The results from the present study are consistent with previous EDITION studies and extend these findings to Japanese people with type 2 diabetes.…”
Section: Discussionsupporting
confidence: 91%
